1. Home
  2. YALA vs ANAB Comparison

YALA vs ANAB Comparison

Compare YALA & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • YALA
  • ANAB
  • Stock Information
  • Founded
  • YALA 2016
  • ANAB 2005
  • Country
  • YALA United Arab Emirates
  • ANAB United States
  • Employees
  • YALA N/A
  • ANAB N/A
  • Industry
  • YALA Computer Software: Programming Data Processing
  • ANAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • YALA Technology
  • ANAB Health Care
  • Exchange
  • YALA Nasdaq
  • ANAB Nasdaq
  • Market Cap
  • YALA N/A
  • ANAB 759.5M
  • IPO Year
  • YALA 2020
  • ANAB 2017
  • Fundamental
  • Price
  • YALA $7.17
  • ANAB $19.58
  • Analyst Decision
  • YALA
  • ANAB Buy
  • Analyst Count
  • YALA 0
  • ANAB 10
  • Target Price
  • YALA N/A
  • ANAB $37.75
  • AVG Volume (30 Days)
  • YALA 1.9M
  • ANAB 605.6K
  • Earning Date
  • YALA 05-19-2025
  • ANAB 05-05-2025
  • Dividend Yield
  • YALA N/A
  • ANAB N/A
  • EPS Growth
  • YALA 13.85
  • ANAB N/A
  • EPS
  • YALA 0.74
  • ANAB N/A
  • Revenue
  • YALA $339,675,845.00
  • ANAB $111,872,000.00
  • Revenue This Year
  • YALA $9.21
  • ANAB N/A
  • Revenue Next Year
  • YALA $5.98
  • ANAB $44.69
  • P/E Ratio
  • YALA $9.86
  • ANAB N/A
  • Revenue Growth
  • YALA 6.52
  • ANAB 387.20
  • 52 Week Low
  • YALA $3.71
  • ANAB $12.21
  • 52 Week High
  • YALA $8.29
  • ANAB $41.31
  • Technical
  • Relative Strength Index (RSI)
  • YALA 59.94
  • ANAB 48.91
  • Support Level
  • YALA $6.51
  • ANAB $19.57
  • Resistance Level
  • YALA $7.48
  • ANAB $21.52
  • Average True Range (ATR)
  • YALA 0.55
  • ANAB 1.19
  • MACD
  • YALA -0.09
  • ANAB -0.22
  • Stochastic Oscillator
  • YALA 40.74
  • ANAB 26.72

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: